Hyperion DeFi, Inc. (NASDAQ:HYPD) Given Average Rating of “Hold” by Brokerages

Hyperion DeFi, Inc. (NASDAQ:HYPD) has earned a consensus rating of “Hold” from the five analysts that are currently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, two have given a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $4.5833.

Several analysts have issued reports on HYPD shares. Zacks Research raised shares of Hyperion DeFi to a “hold” rating in a research report on Monday, December 29th. Cantor Fitzgerald initiated coverage on shares of Hyperion DeFi in a research note on Tuesday, December 16th. They issued an “overweight” rating and a $4.00 target price for the company. Wall Street Zen raised shares of Hyperion DeFi from a “sell” rating to a “hold” rating in a research note on Saturday, November 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Hyperion DeFi in a report on Thursday, January 22nd. Finally, Chardan Capital set a $7.75 price objective on shares of Hyperion DeFi and gave the company a “buy” rating in a research report on Wednesday, December 24th.

Hyperion DeFi Price Performance

HYPD stock opened at $3.22 on Thursday. The firm has a market cap of $26.31 million, a P/E ratio of -0.80 and a beta of 2.69. The company has a debt-to-equity ratio of 0.11, a quick ratio of 2.25 and a current ratio of 2.25. Hyperion DeFi has a 1 year low of $0.85 and a 1 year high of $17.18. The stock has a 50-day simple moving average of $3.56 and a 200-day simple moving average of $5.78.

Insiders Place Their Bets

In other Hyperion DeFi news, Director Ellen R. Strahlman acquired 19,702 shares of the stock in a transaction on Thursday, December 18th. The stock was purchased at an average price of $3.14 per share, for a total transaction of $61,864.28. Following the purchase, the director directly owned 95,150 shares in the company, valued at $298,771. This trade represents a 26.11% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Happy David Walters acquired 61,930 shares of the company’s stock in a transaction on Wednesday, December 17th. The shares were acquired at an average price of $3.02 per share, for a total transaction of $187,028.60. Following the completion of the acquisition, the director directly owned 111,930 shares in the company, valued at $338,028.60. The trade was a 123.86% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Over the last three months, insiders bought 189,204 shares of company stock worth $611,467. Company insiders own 10.86% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the company. Formidable Asset Management LLC acquired a new stake in Hyperion DeFi in the fourth quarter worth $83,000. Nations Financial Group Inc. IA ADV bought a new stake in Hyperion DeFi in the 4th quarter valued at about $40,000. Sanctuary Advisors LLC acquired a new position in Hyperion DeFi during the 4th quarter valued at about $38,000. Investment House LLC acquired a new position in Hyperion DeFi during the 4th quarter valued at about $166,000. Finally, Geode Capital Management LLC bought a new position in Hyperion DeFi in the 4th quarter worth about $214,000. Institutional investors own 25.84% of the company’s stock.

Hyperion DeFi Company Profile

Eyenovia, Inc, an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis.